Ventyx Biosciences (VTYX) 주식
헬스케어 부문 기업. 11월 2026 기준 Ventyx Biosciences의 주가, 사업 개요, 알아두어야 할 핵심 정보를 정리했습니다.
Ventyx Biosciences, Inc. (VTYX) is a small‑cap biotechnology company listed in the US market with a market capitalisation of about $268.12 million. As an R&D‑focused issuer, Ventyx’s value is driven primarily by its scientific pipeline, clinical‑trial progress, regulatory milestones and partnerships rather than steady operating profits. Biotech stocks of this size often experience high volatility: positive trial news or regulatory approvals can lift the share price quickly, while setbacks, funding needs or disappointing data can lead to sharp declines. Income investors should not expect dividends; returns typically come from capital appreciation. Before considering any exposure, investors should review the company’s latest filings, understand the clinical stage of its programmes, assess cash runway and funding plans, and be comfortable with possible dilution and binary event risk. This summary is for general educational purposes only and is not personalised investment advice — values can rise and fall and past performance is not a reliable indicator of future results.
Ventyx Biosciences (VTYX) 주식 전망
애널리스트 목표 주가, 향후 12개월
$12.25
-12.5% 오늘 $14.00 대비
최근 12개월 가격 범위
12개월 범위의 중간
Ventyx Biosciences을(를) 담당하는 애널리스트들의 12개월 컨센서스 목표 주가는 $12.25으로, 현재가 $14.00 대비 낮은 수준입니다.
애널리스트 목표 주가는 의견이며 보장이 아닙니다. 원금 손실 위험이 있습니다. 26 5월 2026 기준 데이터입니다.
출처: 애널리스트 심리 지표는 4만 곳 이상의 기업 고객을 보유한 글로벌 금융 시장 데이터 선두 기업 Refinitiv Ltd가 제공합니다. Refinitiv Ltd는 Nemo와 무관한 독립적인 제3자입니다. 본 내용은 투자 조언이 아닙니다.
6개월 성장 성과
주가 성과 요약
애널리스트 평가
Analysts suggest holding Ventyx Biosciences' stock as its target price indicates limited growth potential.
재무 건전성
Ventyx Biosciences is showing strong financial performance with solid cash flow and book value per share.
앱을 무료로 다운로드하고 더 많은 종목 보기
60초면 충분합니다.
VTYX이(가) 포함된 바스켓
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
게시일: 2025년 11월 17일
바스켓 살펴보기Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
게시일: 2025년 11월 16일
바스켓 살펴보기M&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
게시일: 2025년 11월 15일
바스켓 살펴보기Rinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
게시일: 2025년 10월 21일
바스켓 살펴보기Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
게시일: 2025년 10월 5일
바스켓 살펴보기Lottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
게시일: 2025년 6월 17일
바스켓 살펴보기이 종목을 주목해야 하는 이유
Small‑cap dynamics
Market moves can be large and rapid for a ~$268m company, offering potential upside but also heightened volatility and liquidity risk.
Pipeline & trials
Clinical progress and regulatory news typically drive value. Check trial phases and read peer comparisons, though outcomes can be binary.
Funding considerations
R&D costs may require future capital raises, which can dilute shareholders; assess cash runway and management funding plans.
왜 Nemo와 함께 투자해야 할까요?
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.